We are live on ! Find out more

ImmunityBio

IBRX

Market cap $8.65B

8.16 USD

+0.44

5.7%

At close Updated Sep 11, 11:40 AM EDT

1 day

5.7%

5 days

0.99%

1 month

7.37%

3 months

13.33%

6 months

-1.33%

Year to date

303.96%

1 year

215.06%

5 years

-16.48%

10 years

-7.8%

About: ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Employees: 691

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 53.3%

Neutral 46.7%

Negative 0%

Undercovered Dozen: Blue Owl Capital, Archer Aviation, Apollo Commercial And More

The Undercovered Dozen series spotlights 12 lesser-covered stocks featured on Seeking Alpha. This curated selection aims to provide fresh investment ideas and foster community discussion around under-the-radar equities. Readers are encouraged to engage, share perspectives, and highlight additional overlooked investment opportunities.

Undercovered Dozen: Blue Owl Capital, Archer Aviation, Apollo Commercial And More

Zacks Investment Research

Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?

ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?

Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?

ImmunityBio: None Of The Moonshots Is Priced In

ImmunityBio is rated a strong buy, driven by ANKTIVA's FDA approval for BCG-unresponsive NMIBC and significant pipeline expansion potential. Current valuation reflects success in bladder cancer and BCG-naïve expansion, but assigns limited value to systemic immunotherapy potential in NSCLC or other types of cancer. Key near-term catalysts include phase 3 NSCLC data and BCG-naïve bladder cancer trial results, both of which could unlock substantial upside.

ImmunityBio: None Of The Moonshots Is Priced In

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and global relationships. He will report to Executive Chairman and Founder Dr. Patrick Soon-Shiong. The Office of the Executive Chairman will bring together senior leade.

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

Zacks Investment Research

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

Zacks Investment Research

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.1 per share a year ago.

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30, 2026. Net product revenue reached $50.7 million, representing 92% year-over-year growth and 15% sequential growth from the first quarter of 2026. The Company also advanced multiple regulatory and clinical programs across its immunotherapy pipeline while achieving its eighth consecutive quarter of.

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

The Emirates Drug Establishment (EDE) in the United Arab Emirates on Thursday approved ImmunityBio Inc.'s (NASDAQ:IBRX) immunotherapy drug, ANKTIVA.

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has granted Marketing Authorization for ANKTIVA® (nogapendekin alfa inbakicept) across two indications. The authorization covers ANKTIVA 0.4 mg in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC, and ANKTIVA 1.2 mg in combination wit.

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)

ImmunityBio earns a cautious buy rating as Anktiva demonstrates strong efficacy and safety in NMIBC and shows promise across broader oncology indications. IBRX's valuation now reflects significant future revenue; rapid share appreciation and anticipated dilution temper near-term upside despite robust revenue ramp and pipeline catalysts. Anktiva's combination with BCG outperforms competitors, with 84% CR in BCG-naïve NMIBC and potential label expansion pending FDA decision in early 2027.

ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)

See News Rankings

Price charts implemented using Lightweight Charts™